Why AngioDynamics Stock Is Crashing Today

Core Viewpoint - AngioDynamics experienced a significant decline in share price following its fiscal Q1 2025 update, which revealed mixed financial results and a net loss, despite maintaining its full-year guidance [1][2]. Financial Performance - AngioDynamics reported fiscal Q1 net sales of $67.5 million, reflecting a year-over-year increase of 1.1%, but falling short of analysts' expectations of $67.93 million [1]. - The company posted a net loss of $12.8 million, equating to $0.31 per share under GAAP, while the adjusted net loss was $4.4 million, or $0.11 per share, which was better than the consensus estimate of an adjusted loss of $0.15 per share [1]. Regulatory Developments - AngioDynamics submitted results from a pivotal study of the NanoKnife system to the FDA, aiming for 510(k) clearance for prostate tissue ablation in intermediate-risk patients [2]. - The company received European CE Mark approval for its Auryon Atherectomy System, which is used for treating peripheral artery disease, having previously been cleared by the FDA in 2020 [2]. Future Guidance - Despite the mixed fiscal Q1 results, AngioDynamics maintained its full-year guidance, expecting net sales between $282 million and $288 million, indicating year-over-year growth of 4.2% to 6.4% [2]. - The company projects an adjusted net loss per share between $0.38 and $0.42, an improvement compared to a pro forma adjusted loss per share of $0.45 in fiscal 2024 [2].